Merfyn H. Williams
Plus aucun poste en cours
Profil
Merfyn H.
Williams is Vice President of Regulatory Affairs for Napo Pharmaceuticals, Inc. He has 20 years of pharmaceutical experience, including 8 years with the US Food and Drug Administration.
Dr. Williams held various positions at Bayer Corp.
and Glaxo Smithkline.
From 2004 to 2006, he was Senior Director of Regulatory Affairs for Intarcia Therapeutics, Inc. From 2000 to 2004, Dr. Williams was Senior Director of Regulatory Affairs for Biotechnology Products for Bayer Corp.
He worked at Sequella Foundation and CL McIntosh & Associates.
Dr. Williams was in the Center for Biologics Evaluation and Research.
He received a BS degree in Bacteriology from the University of Birmingham in UK and a PhD in Clinical Immunology from the Welsh National School of Medicine.
Anciens postes connus de Merfyn H. Williams
| Sociétés | Poste | Fin |
|---|---|---|
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Conseiller Juridique Général | 01/01/2006 |
Bayer Corp.
 Bayer Corp. Pharmaceuticals: MajorHealth Technology Bayer Corp. manufactures and markets pharmaceutical, healthcare, nutrition and materials products. The firm offers consumer care, diagnostics, diabetes and animal health products. It also provides material science products, which include coating, adhesive and sealant raw materials polycarbonates polyurethanes and thermoplastic polyurethane elastomers. The company was founded in 1973 and is based in Whippany, NJ. | Conseiller Juridique Général | 01/01/2004 |
Napo Pharmaceuticals, Inc.
 Napo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Napo Pharmaceuticals, Inc. provides pharmaceutical products for gastro-intestinal disorders. The company was founded by Lisa A. Conte in November 2001 and is headquartered in San Francisco, CA. | Conseiller Juridique Général | - |
Formation de Merfyn H. Williams
| University of Birmingham | Undergraduate Degree |
| University of Wales (Bangor) | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Napo Pharmaceuticals, Inc.
Napo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Napo Pharmaceuticals, Inc. provides pharmaceutical products for gastro-intestinal disorders. The company was founded by Lisa A. Conte in November 2001 and is headquartered in San Francisco, CA. | Health Technology |
Bayer Corp.
Bayer Corp. Pharmaceuticals: MajorHealth Technology Bayer Corp. manufactures and markets pharmaceutical, healthcare, nutrition and materials products. The firm offers consumer care, diagnostics, diabetes and animal health products. It also provides material science products, which include coating, adhesive and sealant raw materials polycarbonates polyurethanes and thermoplastic polyurethane elastomers. The company was founded in 1973 and is based in Whippany, NJ. | Health Technology |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
